Physician profile
Hailing Zhang
NPI 1346331675
$1,757.93
in general payments reported to CMS, 2019-2025
23 companies · $466 in 2025
The $466 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2020: $43.59 · 2021: $12.46 · 2022: $138 · 2023: $351 · 2024: $586 · 2025: $466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,388 · Education: $15.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,387.50 |
| Education | $15.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $421.35 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $267.57 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Alkermes, INC. | $190.43 | 2023-2025 | Lybalvi, Aristada |
| Janssen Pharmaceuticals, INC | $174.38 | 2019-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $140.64 | 2022-2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $75.89 | 2022-2024 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $63.71 | 2019-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $59.78 | 2019-2025 | Fanapt |
| Bausch Health US, LLC | $47.31 | 2025 | Wellbutrin |
| Lundbeck LLC | $45.02 | 2022-2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $42.53 | 2019-2020 | |
| Almatica Pharma LLC | $42.11 | 2022-2024 | Loreev Xr, Gralise, Sertraline Hcl |
| Merck Sharp & Dohme LLC | $29.71 | 2019-2024 | Verquvo |
| Janssen Scientific Affairs, LLC | $19.00 | 2025 | Spravato |
| Glaxosmithkline, LLC. | $18.84 | 2023 | Trelegy Ellipta |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $18.65 | 2022 | |
| Neurocrine Biosciences, INC. | $17.49 | 2025 | |
| Eisai INC. | $16.15 | 2024 | |
| Avanir Pharmaceuticals, INC. | $14.54 | 2019 | |
| Jazz Pharmaceuticals INC. | $14.19 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.15 | 2022 | |
| Allergan, INC. | $13.15 | 2020 | |
| Novo Nordisk INC | $11.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hailing Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.